Report Overview

China Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics market size stood at around USD 0.0466 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Neuromyelitis optica spectrum disorder (NMOSD) is a severe inflammatory disease of the central nervous system (CNS) with preferential involvement of the optic nerve and spinal cord. NMOSD has an estimated annual incidence of 40,000 in China, with 60% of patients relapse in one year. The peak incidence was among those aged 4565 years, mainly in females, the female to male ratio is 4.71:1. From 2015 to 2019, in China the prevalence of NMOSD in adults increased from 37200 to 39200. Approximately 80% of the NMOSD patient population are AQP4+ cases, in which a persons own immune system attacks the astrocytes of the optic nerve, spinal cord and brainstem.



Market Drivers

China is a growing market for neuromyelitis optica spectrum disorder (NMOSD) disease due to increase in Chinas prevalence rate (From 2015 to 2019, the prevalence of NMOSD in adults increased from 37200 to 3920) and improvement in healthcare facilities. In addition to these, the emergence of biologics and adoption of novel therapeutics are further pushing the market growth.Other factors that contribute to the growth of the market are increase in population and government initiatives.

Less trained expertise or technically skilled professionals coupled with high treatment cost significantly hinder the growth of neuromyelitis optica spectrum disorder (NMOSD) therapeutics market.